Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

What have we learned from SHIVA?

The SHIVA trial compared the efficacy of targeted agents selected on the basis of tumour molecular profiling (using an algorithmic approach) with that of physician's choice across multiple solid tumours; the trial was negative for the primary end point. We now discuss the challenges associated with precision medicine trial design and propose solutions learned from this trial.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Le Tourneau, C. et al. The spectrum of clinical trials aiming at personalizing medicine. Chin. Clin. Oncol. 3, 13 (2014).

    PubMed  Google Scholar 

  2. Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324–1334 (2015).

    Article  CAS  Google Scholar 

  3. von Hoff, D. D. et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877–4883 (2010).

    Article  CAS  Google Scholar 

  4. Le Tourneau, C. et al. SHIVA: randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer — PFS ratio from patients who crossed-over [abstract]. J. Clin. Oncol. 34, 2535 (2016).

    Article  Google Scholar 

  5. Schwaederle, M. et al. Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. Mol. Cancer Ther. 15, 743–752 (2016).

    Article  CAS  Google Scholar 

  6. Wheler, J. J. et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 76, 3690–3701 (2016).

    Article  CAS  Google Scholar 

  7. Le Tourneau, C. et al. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. J. Natl Cancer Inst. 108, djv362 (2015).

    Article  Google Scholar 

  8. Jardim, D. L. et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J. Natl Cancer Inst. 107, djv253 (2015).

    Article  Google Scholar 

  9. Janku, F. et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 6, 377–387 (2014).

    Article  CAS  Google Scholar 

  10. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the Joan and Irwin Jacobs Fund. The SHIVA trial was supported by the grant ANR-10-EQPX-03 from the Agence Nationale de le Recherche (Investissements d'avenir) and SiRIC (Site de Recherche Intégré contre le Cancer).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christophe Le Tourneau.

Ethics declarations

Competing interests

C.L.T. has received consultant fees from Debiopharm, GamaMabs, Merck Serono, MSD and Novartis. R.K. receives funding from Foundation Medicine, Genentech, Guardant, Merck Serono, Pfizer and Sequenom, consultant fees from Actuate Therapeutics and X-Biotech, and owns equity in CureMatch and Novena.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Le Tourneau, C., Kurzrock, R. What have we learned from SHIVA?. Nat Rev Clin Oncol 13, 719–720 (2016). https://doi.org/10.1038/nrclinonc.2016.164

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.164

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing